Description
This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.
Location: SIMR (Sacramento/Valley Area, Roseville, and Auburn)
Please contact: SIMR@sutterhealth.org about Metastatic (AstraZeneca D533AC00001 MONETTE)
Principal Investigator
Co-Investigator(s)
Vijay Suhag, M.D., Dron Gauchan, MD, Kristin N. Arreola, M.D., Kristie A. Bobolis, M.D., Rajeswari Chellappah, M.D., Jaspreet K Dhillon, Medical Oncologist, Brian K. Kim, M.D, Sivakumar Reddy, M.D.
Related Studies
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D., External PI, Principal Investigator
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: Su-Ying Liang, Ph.D., External PI, Principal Investigator
Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator